Vækstaktier

2cureX har her til morgen meddelt, at de har udvidet deres produktportefølje.

2crureX har nu også en godkendt test indenfor 3rd line behandling af metastatisk tyktarms kræft. Testen er den tredje, som 2cureX kan tilbyde inden for metastatisk tyktarms kræft, hvor de nu tilbyder test til 1st, 2nd og 3rd line behandling.

Den nye test kaldes IndiTreat® mCRC Explore, og giver mulighed for at de professionelle onkologer, kan tilbyde en alternativ behandling. Gennem studiet TICC1 identificerede 2cureX patienter, som fik en fordel af at blive behandlet med medicin, som ikke var henvendt den specifikke kræfttype. Med lanceringen af testen til 3rd line behandling har 2cureX nået deres portfolio rollout plan for 2022.

I denne forbindelse udtaler CSO, Ole Thastrup:

With this new test we offer a complete portfolio in metastatic colorectal cancer, supporting treatment decision-making in 1st, 2nd and 3rd line. Back in October we had announced the goal of having three tests in the market in 2022, and we are proud of having achieved that goal before we anticipated. We will now continue advancing our ongoing projects in non-metastatic colorectal cancer, pancreatic cancer, and ovarian cancer, although the upcoming IVD-R will result in longer product development processes.